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Background: Although a variety of drugs have been used to treat the symptoms of rheumatoid arthritis (RA), none
of them are able to cure the disease. Interferon β (IFN-β) has pleiotropic effects on RA, but whether it can be used
to treat RA remains globally controversial. Thus, in this study we tested the effects of IFN-β on RA patients and on
collagen antibody-induced arthritis (CAIA) model mice.
Methods: The cytokine and auto-antibody expression profiles in the serum and synovial fluid (SF) from RA patients
were assessed using enzyme-linked immunosorbent assay (ELISA) and compared with the results from osteoarthritis
(OA) patients. Exogenous IFN-β was administered to RA patients and CAIA model mice, and the therapeutic effects
were evaluated. Endogenous IFN-β expression in the joint bones of CAIA model mice was evaluated by quantitative
real-time PCR (qRT-PCR). The effects of exogenous IFN-β on CAIA model mice were assessed using a clinical scoring
system, hematoxylin eosin and safranin-O with fast green counterstain histology, molybdenum target X-ray, and
tartrate-resistant acid phosphatase (TRAP) staining. The RANKL-RANK signaling pathway was analyzed using qRT-PCR. The
RAW 264.7 cell line was differentiated into osteoclasts with RANKL stimulation and then treated with exogenous IFN-β.
Results: The expression of inflammatory cytokines (IFN-γ, IL-17, MMP-3, and RANKL) and auto-antibodies (CII antibodies,
RF-IgM, and anti-CCP/GPI) were significantly higher in RA compared with OA patients. After IFN-β intervention, some
clinical symptoms in RA patients were partially alleviated, and the expression of IFN-γ, IL-17, MMP-3, and OPG)
returned to normal levels. In the CAIA model, the expression of endogenous IFN-β in the joint bones was decreased.
After IFN-β administration, the arthritis scores were decreased; synovial inflammation, cartilage, and bone destruction
were clearly attenuated; and the expression of c-Fos and NFATc1 were reduced, while RANKL and TRAF6 expression
was unchanged. In addition, exogenous IFN-β directly inhibited RANKL-induced osteoclastogenesis.
Conclusions: Exogenous IFN-β administration immunomodulates CAIA, may reduce joint inflammation and, perhaps
more importantly, bone destruction by inhibiting the RANKL-c-Fos signaling pathway. Exogenous IFN-β intervention
should be selectively used on RA patients because it may only be useful for RA patients with low endogenous IFN-β
expression.
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Rheumatoid arthritis (RA) is an autoimmune disease
that is characterized by chronic inflammation of the syn-
ovial joints, with subsequent progressive erosion and de-
struction of the articular tissues [1,2]. RA affects around
1% of the population and is associated with significant
morbidity and mortality [3]. Although a variety of drugs
have been used to treat the symptoms, none of them are
able to cure the disease. Disease-modifying anti-rheumatic
drugs, such as methotrexate, are one of the most common
types of treatments. Other efficient anti-rheumatic drugs
have recently been developed, including biological re-
sponse modifiers such as tumor necrosis factor (TNF)-α
blockers [4,5]. However, the clinical use of these therapies
is limited because of their adverse effects and high cost.
Therefore, developing novel therapies is crucial for RA
patients.
For many years, IFN-β was assumed to be beneficial for
the treatment of a variety of immune mediated diseases.
When administered to multiple sclerosis (MS) patients,
IFN-β reduces the relapse rate, decreases the disease activ-
ity on magnetic resonance imaging (MRI) scans, and de-
lays the progression of disability [6,7]. IFN-β has clear
anti-inflammatory properties, and, moreover, it plays an
important role in maintaining bone homeostasis by
inhibiting osteoclastogenesis. IFN-β may be an effective
treatment for RA [8,9]. Previous studies have shown that
IFN-β therapy is effective in murine models of arthritis;
however, systemic IFN-β treatment results in only min-
imal improvement in RA [8,10,11]. In order to assess
the effects of IFN-β on RA, exogenous IFN-β was ad-
ministered to RA patients and collagen antibody-induced
arthritis (CAIA) model mice in this study. The mechanism
of beneficial IFN-β effects on CAIA was also evalu-




Patients with RA or osteoarthritis (OA) were enrolled in
this study from 2008 to 2013 in the Shanghai Guanghua
Hospital of Integrated Traditional Chinese and Western
Medicine (Shanghai, China). All the RA patients fulfilled
the 1987 revised criteria of the American College of
Rheumatology (formerly the American Rheumatism Asso-
ciation) [12,13], and the OA patients fulfilled the American
College of Rheumatology criteria [14]. Informed consent
was obtained from each participant, and the experimental
protocol was approved by the hospital’s Human Research
Ethics Committee.
Exogenous IFN-β intervention in RA patients
Twenty RA patients were selected for an immune interfer-
ence study with exogenous IFN-β (Rebif®, Merck Serono,Darmstadt, Germany) administered as in the MS and
phase I clinical trials for RA patients [7,12]. A clinical as-
sessment was performed by evaluating the duration of
morning stiffness (min), the number of painful joints and
swollen joints, and the degree of pain (by Visual Analog
Scale [VAS]) in RA patients both before and after exogen-
ous IFN-β administration.
Enzyme-linked immunosorbent assay (ELISA)
Peripheral blood samples from 22 RA and 13 OA patients,
as well as synovial fluid (SF) from 21 RA and 5 OA pa-
tients, were collected under aseptic conditions. The levels
of inflammatory cytokines interleukin-17 (IL-17), inter-
feron γ (IFN-γ), tissue inhibitor of metalloproteinases 1
(TIMP-1), matrix metalloproteinase 3 (MMP-3), osteopro-
tegerin (OPG), and receptor activator of nuclear factor κB
(RANKL), as well as CII antibody, rheumatoid factor-IgM
(RF-IgM), anti-cyclic citrullinated peptide antibody (CCP),
and glucose-6-phosphate isomerase antibodies (GPI) were
detected using Quantikine ELISA kits (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s
instructions. Thresholds of CII IgA/CII IgG >2.2 U/mL,
CII IgM >2.4 U/mL, RF-IgM >20 U/mL, GPI >2.0 mg/L,
and anti-CCP >5 U/mL were used to identify positive
samples according to the standards of the clinical la-
boratory of Shanghai Guanghua Hospital of Integrated
Traditional Chinese and Western Medicine.
Animals
BALB/c mice (20–23 g, 8–10 weeks) were purchased from
the Chinese Academy of Sciences, Shanghai Laboratory
Animal Center and housed following institutional guide-
lines. Experiments were conducted according to the
guidelines of the Ethics Committee of Laboratory Animals
Welfare of Shanghai Jiao Tong University School of
Medicine.
Induction of CAIA and establishment of the treatment
protocol
To induce the CAIA model, BALB/c mice were injected
with 2 mg of collagen antibody cocktail (Chondrex,
Redmond, WA, USA) intravenously on Day 1, and were
then treated with 25 μg of lipopolysaccharide (LPS) intraper-
itoneally on Day 4. All the mice were monitored daily for
arthritis. Each paw was scored for clinical signs of arthritis
as follows: normal (0); erythema and edema in only one digit
(0.5); erythema and mild edema of the footpad, ankle, or
two to five digits (1); erythema and moderate edema of two
joints (footpad, ankle, or two to five digits) (2); erythema
and severe edema of the entire paw (3); reduced swell-
ing and deformation leading to incapacitation of the
limb (4). Each mouse arthritic score was obtained by
summing the scores recorded for each paw. The clinical
evaluations were performed by two blinded investigators,
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4, after LPS injection, the intervention group CAIA model
mice (n = 9) received 10,000 IU of exogenous mouse IFN-
β (PBL interferon source, Piscataway, NJ, USA) every day
by intraperitoneal injection for 4 days, while the control
group (non-intervention group) CAIA model mice (n = 9)
were similarly treated with sterile saline.
Molybdenum X-ray imaging
Prior to histology, molybdenum X-ray radiographs (Adobe
Systems, Munich, Germany) of the knees and paws of
each mouse were taken on day 12 after induction of arth-
ritis. The limbs were extended to prevent joint buckling,
and the bone mineral density was assessed.
Histology
At day 12 after induction of arthritis, the knees and paws
were harvested and fixed in 4% paraformaldehyde,
decalcified, and embedded in paraffin. Serial sections
of the knees and paws were stained with hematoxylin
and eosin (H&E, Sakura Finetek, Tokyo, Japan) or
safranin-O with fast green counterstain. Inflammation
and joint damage were scored on a scale of 0 (no in-
flammation) to 3 (severe inflammation) depending on
the number of inflammatory cells. Cartilage destruction
was scored on a scale of 0 (no loss) to 3 (complete loss of
the articular cartilage). Scoring was performed by two
blinded investigators, and the mean of both scores was
calculated.
Quantitative real-time polymerase chain reaction
(qRT-PCR)
The hind paws and joint bones of the CAIA model mice
were pulverized in liquid nitrogen, and the total RNA was
extracted using TRIzol® reagent (Invitrogen, Carlsbad, CA,
USA). One μg of the total RNA was reverse transcribed
using a reverse transcription kit (Promega, Madison, WI,
USA). Quantitative real-time PCR (qRT-PCR) was per-
formed with duplicate samples on the ABI7500 system
(Applied Biosystems, Darmstadt, Germany) under the
following conditions: 2 min of polymerase activation at
95°C followed by 45 cycles of 10 sec denaturation at
95°C and 30 sec annealing and extension at 60°C. The de-
tection threshold was set to the log linear range of the amp-
lification curve and kept constant (0.05) for all data analysis.
Threshold cycle (CT) of each target product was determined
and set in relation to the amplification plot of β-actin. Differ-
ences in the CT values (ΔCT) between each gene and β-actin
were used to calculate the relative expression (relative ex-
pression = 2−(CT of target genes− CT of β-actin) =2−ΔCT). The
mouse PCR primers (Sangon Biotech, Shanghai, China)
used for RT-PCR were as follows: for IFN-β, sense: 5′-CGT
TCCTGCTGTGCTTCTC-3′ and anti-sense: 5′-TGTAAC
TCTTCTCCATCTGTGAC-3′; TIMP-1, sense: 5′-GCCGCCATCATCGCAGAT-3′ and anti-sense: 5′- CCTTATGAC
CAGGTCCGAGTTG-3′; MMP-3, sense: 5′- AAGAGAT
CCAAGGAAGGCATCCT-3′ and anti-sense: 5′- GGTTCT
GCCATAGCACATGCT-3′; TRAP, sense: 5′-AAATCACT
CTTCAAGACCAG-3′ and anti-sense: 5′-TTATTGAAC
AGCAGTGACAG-3′; RANKL, sense: 5′-TGCCGCTACC
GCAAGACAGA-3′ and anti-sense: 5′-GCAGGCTTACG
TTGGCTCCC-3; TRAF-6, sense: 5′-GCTCAAACGGACC
ATTCGGA-3′ and anti-sense: 5′-GGGATTGTGGGTCG
CTGAAA-3′; c-Fos, sense: 5′-CCCTTTGATGACTTCTT
GTTTCCG-3′ and anti-sense: 5′-AATTGCTGTGCAGA
GGCTCCC-3′; NFATc1, sense: 5′-TCTCGAAAGACAGC
ACTGGAGCAT-3′ and anti-sense: 5′-ACGGGATCTCCA
GGAATTTGGTGT-3′; β-actin, sense: 5′-CTGTCCCTGT
ATGCCTCTG-3′ and anti-sense: 5′-ATGTCACGCACGA
TTTCC-3′.
Cell culture and differentiation
The murine macrophage cell line RAW 264.7 (gener-
ously provided by Dr. J. Luo, East China Normal Univer-
sity) was plated in 24-well plates (10,000 cells per well)
containing α-minimum essential medium (α-MEM) sup-
plemented with 10% fetal calf serum (FCS). The cells
were stimulated with 50 ng/mL RANKL (R&D Systems)
with or without exogenous mouse IFN-β (50 IU/mL) for
4 days. All cells were cultured in a 5% CO2/95% air incuba-
tor. The culture medium was replaced with fresh medium
every day.
Tartrate-resistant acid phosphatase (TRAP) staining
The paraffin-embedded sections of the joint bones of the
CAIA model mice and RANKL-induced osteoclastogenesis
on the fourth day after induction were gently washed twice
with pre-warmed, double-distilled water (37°C), fixed with
stationary liquid for 20 sec, and stained with tartrate-
resistant acid phosphatase (TRAP, Sigma, St. Louis, MO,
USA) for 60 min at 37°C. The TRAP-stained cells were
then gently washed, counterstained in the dark with
hematoxylin or 100 μL/well of 300 nM diamidino-2-
phenylindole (DAPI ) in phosphate buffer solution (PBS)
containing 0.1% Triton X-100 at room temperature for
15 min, and examined with a ZEISS Vert.A1 microscope
(Carl Zeiss, Oberkochen, Germany). TRAP-positive
cells appeared dark red, and TRAP-positive multi-
nucleated cells containing three or more nuclei were
counted as osteoclasts. Osteoclasts were quantified
by imaging five fields of view under 200× magnification
and directly counting the number of TRAP-positive cells
[16]. All experiments were carried out in triplicate at
least 3 times.
Statistical analyses
Statistical analyses were performed in Prism (GraphPad
Software, La Jolla, CA, USA). Values are presented as
Figure 1 The expression of inflammatory factors in the serum and SF of RA patients. The levels of IFN-γ (A) and IL-17 (B) in the RA SF were
compared with that in RA serum and OA SF. The levels of MMP-3 (C) and TIMP-1 (D) in the serum and SF of RA patients were assessed. The levels
of RANKL in RA serum (E) and SF (F) were compared with those in OA serum and SF. *: P <0.05, **: P <0.01.
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t-tests were used for parametric outcomes to compare
groups. The Kruskal–Wallis test for several group means
followed by the Mann–Whitney U test for comparison of
two groups [17] were also used. P-values <0.05 were con-
sidered statistically significant. *: P <0.05, **: P <0.01.Results
Differences in the level of inflammatory factors and
auto-antibodies between RA and OA patients
The level of inflammatory factors assessed by ELISA in
RA serum and SF were compared with those in OA
serum and SF. IFN-γ and IL-17 were significantly higher
Table 1 The fraction of samples positive for CII IgA, IgG,
and IgM in RA and OA serum and SF
Group CII antibody
IgG(+/-) IgA(+/-) IgM(+/-)
RA Serum (n = 22) 6/16 4/18 3/19
OA Serum (n = 6) 2/4 2/4 2/4
RA SF (n = 21) 15/6* 8/13 12/9
OA SF (n = 5) 0/5* 0/5 1/4
CII: collagen II; RA: rheumatoid arthritis; OA: osteoarthritis; SF: synovial fluid. *:
P <0.05.
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that in OA SF (Figure 1A,B) (P <0.01). The levels of
MMP-3 and TIMP-1 were higher in RA SF than RA
serum (Figure 1C,D) (P <0.01). The levels of RANKL
were significantly higher in RA serum and SF compared
with that in OA serum and SF (Figure 1E,F) (P <0.01, P
<0.05). For auto-antibodies, the positive rate of IgG
was higher in RA SF than in OA SF (Table 1). The posi-
tive rates of RF-IgM, anti- CCP, and GPI in RA serum
were higher than those in OA serum (Table 2).
Cytokine levels were altered by IFN-β administration
In this preliminary assessment of exogenous IFN-β interven-
tion in RA patients, we found that the clinical symptoms in
some RA patients were partially alleviated, including dur-
ation of morning stiffness (min), number of painful joints
and swollen joints, and the degree of pain reported by pa-
tients. The levels of inflammatory factors (IFN-γ, IL-17,
MMP-3, TIMP-1, OPG, and RANKL) in serum and SF were
assessed by ELISA both before and one week after treatment
with exogenous IFN-β. The levels of IFN-γ and IL-17 ap-
peared to decrease after IFN-β treatment, but there were no
significant differences (Figure 2A,B). After IFN-β treatment,
the MMP-3 level in serum was decreased (P <0.05), but
there was no significant change in the levels of MMP-3 in SF
or TIMP-1 in either serum or SF (Figure 2C,D). After IFN-β
treatment, the OPG level was increased in serum (P <0.05),
but there were no significant changes in the OPG level in SF
or RANKL level in either serum or SF (Figure 2E,F).
Endogenous IFN-β decreased in CAIA model mice, and
exogenous IFN-β may alleviate arthritis severity
The CAIA model was successfully induced, and, on
Day 12, a lower endogenous IFN-β RNA expressionTable 2 The fraction of samples positive for RF-IgM,
Anti-CCP, and GPI in RA and OA serum
Group RF-IgM(+/-) Anti-CCP(+/-) GPI(+/-)
RA serum (n = 22) 17/5* 15/7** 14/8**
OA serum (n = 13) 4/9* 0/13** 2/11**
RF-IgM: rheumatoid factor-IgM; Anti-CCP: anti-cyclic citrullinated peptide
antibody; GPI: glucose-6-phosphate isomerase antibodies; RA: rheumatoid
arthritis; OA: osteoarthritis. *: P <0.05, **: P <0.01.was found in the joints by qRT-PCR (P <0.05 vs. nor-
mal BALB/c mice) (Figure 3A). After IFN-β adminis-
tration, the symptoms of the CAIA mice were alleviated
and the arthritis scores were decreased compared with the
non-intervention group (Figure 3B,C). The incidence of
arthritis in the IFN-β intervention group decreased by
30% (Figure 3D).
Exogenous IFN-β may attenuate bone inflammatory
infiltration and cartilage and bone destruction in CAIA
model mice
The paws and knees of the mice were harvested on Day
12 after injection of the anti-collagen II functional do-
mains antibodies. Compared with the non-intervention
group, the HE and safranin-O with fast green counterstain
staining revealed a decrease in the number of infil-
trated inflammatory cells in the articular cavity (Figure 4A)
(P <0.01) and an attenuation in amount of cartilage de-
struction in the IFN-β intervention group (Figure 4B)
(P <0.05). qRT-PCR was performed to determine the
changes in TIMP-1 and MMP-3 expression in the paws
of the mice. Although the expression of TIMP-1 mRNA
was not changed after IFN-β treatment compared to the
non-intervention group (Figure 4C), the expression of
MMP-3 mRNA, a mediator of cartilage catabolism, was
significantly decreased (Figure 4D) (P <0.05). The joint
bones of the mice were imaged using molybdenum X-ray
to determine the effect of exogenous IFN-β on bone.
Compared with the non-intervention group, the bone
mineral density was increased (Figure 5A), while the
osteoclast marker TRAP mRNA level was decreased in
the bones of mouse joints in the IFN-β intervention group
(Figure 5B) (P <0.05). TRAP staining was also performed
to visualize osteoclast infiltration into the bones of mouse
joints, and the results showed that the number of osteo-
clasts was significantly decreased in the IFN-β interven-
tion group (Figure 5C,D) (P <0.05).
RANKL-RANK signaling pathway regulation by exogenous
IFN-β in CAIA model mice
The expression level of osteoclastogenesis-related RANKL-
RANK signaling molecules was detected using qRT-PCR.
While there was no change in the expression of upstream
molecules RANKL and TRAF-6 (Figure 6A,B), the expres-
sion levels of downstream molecules c-Fos and NFATc-1
were significantly decreased in the IFN-β intervention group
compared with the non-intervention group (Figure 6C,D)
(P <0.05).
RANKL-induced osteoclast differentiation by the
RAW264.7 cell line was inhibited by exogenous IFN-β
IFN-β markedly suppressed RANKL-induced osteoclast
differentiation in RAW264.7 cells as assessed using TRAP
and DAPI staining. Four days after RANKL induction, the
Figure 2 Cytokine patterns before and after IFN-β treatment in RA serum and SF. Serum and SF levels of IFN-γ (A), IL-17 (B), MMP-3
(C), TIMP-1 (D), OPG (E), and RANKL (F) in RA patients before and after IFN-β administration. *: P <0.05.
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IFN-β treatment (Figure 7A,B) (P <0.05).
Discussion
To better study RA, it is important to choose a model
that accurately reflects the pathology of RA. The CAIA
mice model is induced by injecting an anti-collagenantibody cocktail followed by injections of LPS, it offers
several key advantages over the classic collagen-induced
arthritis (CIA) model, including a rapid disease onset,
synchronicity, high uptake rate, and the capacity to use
genetically modified mice, such as transgenics and knock-
outs [18-20]. This model replicates many aspects of the
human effector phase of RA [21]. It occurs independently
Figure 3 Endogenous IFN-β expression and the effect of IFN-β treatment on CAIA model mice. The endogenous expression of IFN-β in
the CAIA mice and normal control mice groups (A). Photographs of example hind-paws (B), arthritis scores (C), and the morbidity of arthritis
(D) in the IFN-β intervention and non-intervention groups. *: P <0.05.
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processes to be studied independently of the events that
occur during disease induction [22]. The articular inflam-
mation and cellular infiltration characteristics of the effector
stage are attributable to deposited immune complexes and
activation of complement and Fc receptors (FcR) [21,23].
Cartilage and bone erosion follows the activation of macro-
phages, lymphocytes, and synoviocytes and production of
MMPs and cytokines [21,22].
For the clinical management of RA, a variety of drugs
have been used to improve the symptoms, but none of
them is effective in all RA patients. For example, al-
though TNF inhibitors have been successful in improv-
ing the clinical outcomes for some patients with RA,
other patients do not respond to those treatments. The
nature and pathogenesis of RA are complicated and
likely contribute to the different therapeutic responses.
Thus, the treatment of RA is complex and physicians
must select an effective therapeutic approach for each
patient individually. For example, a prior study suggestedthat patients with increased basal plasma IFN-β activity
respond better to TNF inhibition therapy, while patients
with low basal IFN-β levels respond better to anti-B-cell
therapy [24].
IFN-β was developed as a therapeutic agent for auto-
immune diseases because of its anti-inflammatory activ-
ity. Similar to other biological therapies, this treatment
is not uniformly effective. In the collagen-induced and
adjuvant arthritis animal models, daily systemic adminis-
tration of IFN-β resulted in a reduction in disease activ-
ity and inhibition of cartilage and bone erosion cause by
a significant decrease in TNF and IL-6 expression, as
well as an increase in IL-10 response at the site of in-
flammation [8,17]. Clinical trials using IFN-β for treating
RA have shown conflicting results [11]. Administration
of recombinant IFN-β, in the context of a randomized,
double-blind, placebo-controlled clinical trial for the treat-
ment of patients with active RA, however, showed no
treatment effect on the clinical or radiographic scores
[11]. Consistent with our results, exogenous IFN-β is
Figure 4 Effects of exogenous IFN-β treatment on the inflammation and cartilage destruction in CAIA model mice. The inflammatory
cellular infiltration score (A), cartilage injury (B), and the levels of MMP-3 (C) and TIMP-1 (D) in the IFN-β intervention and non-intervention
groups *: P <0.05.
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RA patients with IFN-β has been unsuccessful so far.
Thus, the results presented in the present study show the
therapeutic use of exogenous IFN-β in RA patients only
partly alleviated the disease symptoms. The results in thepresent study also showed that the expression of endogen-
ous IFN-β in the bones of joints in CAIA model mice was
lower than that in normal mice. Therefore, we treated
CAIA model mice with exogenous IFN-β beginning at the
onset stage, and their arthritis severity was improved,
Figure 5 Effect of exogenous IFN-β administration on the destruction of joint bones. Ankle joint destruction (A), TRAP mRNA level (B), TRAP
staining of joints (C), and the number of TRAP-positive multi-nucleated (≥3 nuclei) cells (D) in the IFN-β intervention and non-intervention groups. *:
P <0.05.
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cartilage and bone in the joint were reduced. Unfortu-
nately, we did not measure the expression of endogenous
IFN-β in the enrolled RA patients. It is suggested that ex-
ogenous IFN-β intervention for RA patients should be
used more selectively, and it is possible that exogenous
IFN-β might only be useful for RA patients who have low
levels of endogenous IFN-β.
The clinical presentation and response to treatment of
RA involves many complex immunological and genetic
interactions. In addition to its critical antiviral and anti-
inflammatory functions, IFN-β also plays an important
role in maintaining bone homeostasis, though the exact
mechanisms by which exogenous IFN-β reduces RA
symptoms, as well as how it maintains bone homeosta-
sis, remain unknown. Accumulating evidence suggests
that the bone destruction in RA is mostly caused by os-
teoclasts [25]. Osteoclasts, derived from monocyte and
macrophage lineage precursor cells, are regulated by the
receptor activator of nuclear factor-κB (NF-κB) ligand(RANKL) and macrophage colony-stimulating factor
(M-CSF). M-CSF promotes osteoclast survival and prolif-
eration, while RANKL is an essential signal for osteoclast
differentiation [26]. RANKL exerts its effects by binding
to RANK in osteoclasts and their precursors. OPG com-
petes with RANKL as an osteoclast-inhibitor [27]. Thus,
the RANKL-RANK signaling pathway is a potential target
for preventing joint destruction in RA patients [28]. After
binding RANKL, RANK activates c-Fos and tumor necro-
sis factor-receptor-associated factor 6 (TRAF6), which al-
lows TRAF6 to stimulate the NF-κB and JNK signaling
pathways. Interestingly, c-Fos can induce endogenous
IFN-β, causing negative feedback regulation of RANKL
signaling: IFN-β activates the transcription factor complex
interferon-stimulated gene factor-3 (ISGF3), which binds
to the interferon-stimulated responsive element (ISRE) on
IFN-inducible genes to suppress RANKL-induced c-Fos
protein expression [29,30]. We propose that the ex-
pression of endogenous IFN-β in some RA patients indi-
cates the activation of an incomplete anti-inflammatory
Figure 7 Effects of exogenous IFN-β administration on RANKL-induced osteoclastogenesis. TRAP staining (A) and the number of TRAP-positive
multi-nucleated (B) RAW264.7 cells after RANKL and exogenous mouse IFN-β treatments or RANKL treatment alone. *: P <0.05.
Figure 6 Changes in the RANKL-RANK signaling pathway after exogenous IFN-β treatment in the CAIA model mice. The levels of RANKL
(A), TRAF6 (B), c-Fos (C), and NFATc-1 (D) in the joints of mice in the IFN-β intervention and non-intervention groups. *: P <0.05.
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haps more importantly, may inhibit bone destruction.
Thus, exogenous IFN-β treatment may be a beneficial
therapeutic strategy for inhibiting bone degradation in
arthritis.
The results of the present study demonstrate for the
first time that daily administration of exogenous IFN-
β, starting at the onset stage of disease, in the murine
CAIA model reduces synovial inflammation and pro-
tects against cartilage and bone destruction. Treat-
ment with exogenous IFN-β also resulted in a reduction
in osteoclastogenesis, which may be explained by the
inhibition of the RANKL-c-Fos signaling pathway
activity.
Conclusions
The marked reduction of arthritic symptoms in CAIA
mice, the changes in synovial tissue and joint bones from
mice with CAIA after exogenous IFN-β intervention,
and the effects of IFN-β on RA patients all support ex-
ogenous IFN-β administration as having immunomodu-
lating effects on the CAIA model, and suggest it may
reduce joint inflammation and, perhaps more import-
antly, bone destruction by inhibiting the RANKL-c-Fos
signaling pathway activity. Exogenous IFN-β administra-
tion should be selectively used in RA patients whose en-
dogenous IFN-β expression is low.
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